Looking for breakthrough ideas for innovation challenges? Try Patsnap Eureka!

Compositions and Methods for Therapy and Diagnosis of Cancer and Cancer Metastasis

a technology for cancer and metastasis, applied in the field of compositions and methods for cancer and cancer metastasis, can solve the problems of analyzing the resected primary tumor to predict the risk of metastasis, it is difficult if not impossible to predict whether a primary tumor has metastasized, and cancer is still among the leading causes of death. it reduces the signaling of constitutive pip3

Inactive Publication Date: 2009-10-08
GANYMED PHARMA AG +1
View PDF1 Cites 0 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Benefits of technology

[0033]The method of diagnosing, monitoring, and / or prognosing cancer, the metastatic behaviour of cancer and / or the presence of a relapse of cancer according to the invention preferably allows the prognosis of a worsened course of a disease, whereby among other things planning of a more aggressive therapy is made possible. This prognostic method also allows to delimit still benign alterations, e.g. hyperplasias, from tumor precursors which are already to be appraised as unfavourable and to anticipate therefore a cancer disposition already before an invasive tumor has formed.

Problems solved by technology

Despite interdisciplinary approaches and exhaustive use of classical therapeutic procedures, cancers are still among the leading causes of death.
Although protein expression profiling, gene array analysis and determination of critical factors in tumor tissue have improved the prognostic classification of tumors, it is still difficult to predict the risk of metastasis analyzing the resected primary tumor.
Presently, it is difficult if not impossible to predict, whether a primary tumor has metastasized or not.
However, it is not yet possible to predict the risk of metastasis by quantification of critical factors in tumor tissue.

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Compositions and Methods for Therapy and Diagnosis of Cancer and Cancer Metastasis
  • Compositions and Methods for Therapy and Diagnosis of Cancer and Cancer Metastasis
  • Compositions and Methods for Therapy and Diagnosis of Cancer and Cancer Metastasis

Examples

Experimental program
Comparison scheme
Effect test

example 1

Materials and Methods

[0203]Tissues and Cell Lines

[0204]This study was approved by the local ethical review board (“Ethikkommission der Ärztekammer des Landes Rheinland-Pfalz”). Recombinant DNA work was done with the official permission and according to the rules of the state government of Rheinland-Pfalz. Tissues were obtained as human surplus materials during routine diagnostic or therapeutic procedures and were stored at −80° C. until use. If not otherwise stated, cell lines were obtained from commercial providers. For demethylation studies cells were split to 20-30% confluency and cultured with 2 μM or 10 μM 5-Aza-2′-deoxycytidine (5-Aza-dC) (Sigma-Aldrich) for 72 h. Colon cancer cell lines HCT116WT, HCT116DNMT1− / −, HCT116DNMT3b− / − and HCT116DKO were kindly provided by Bert Vogelstein.

[0205]RNA-Isolation, RT-PCR and Real-Time RT-PCR

[0206]RNA extraction, first-strand cDNA synthesis, RT-PCR and real-time RT-PCR were performed as previously described (Koslowski, M. et al., Cancer Re...

example 2

TPTE is Ectopically Expressed in Human Tumors

[0230]TPTE mRNA expression was investigated in a large set of normal and neoplastic tissue specimens. TPTE expression is confined to testis and transcript amounts are below detection limit of highly sensitive RT-PCR in all other normal tissue specimens (FIGS. 1a,b). In contrast, strong TPTE expression was detected in 59 of 155 (38%) tumor samples across different cancer types including malignant melanoma (50%), breast carcinomas (47%) and lung carcinomas (55%) as well as in a large set of cancer cell lines (62%) (Tab. 1).

TABLE 1Expression of TPTE in human tissues and cell lines analyzed byRT-PCR and Real-Time PCR.Positive / testedNormal tissuesTestis3 / 3Small intestine0 / 2Colon0 / 3Liver0 / 2Lung0 / 3Lymph node0 / 2Stomach0 / 2Spleen0 / 2Adrenal gland0 / 1Kidney0 / 3Esophagus0 / 1Ovary0 / 2Thymus0 / 1Skin0 / 2Breast0 / 3Pancreas0 / 2PBMC's, resting0 / 3PBMC's, proliferating0 / 3Prostate0 / 2Thyroid0 / 2Endometrium0 / 3Cerebellum0 / 1Brain0 / 2Tumour tissuesBreast cancer17 / 36 (47%)Lun...

example 3

TPTE is a Plasma Membrane PIP3-Phosphatase

[0234]TPTE contains a phosphatase as well as a lipid-binding C2 domain, which have been shown to be essential and sufficient for the lipid phosphatase activity of its homologue PTEN (Lee, J. O. et al., Cell 99, 323-334 (1999)). Whereas a lipid phosphatase activity with substrate-specificity for PIP3 and PI(3,4)P2 has previously been shown for the mouse orthologue of TPTE (Wu, Y. et al., J. Biol. Chem. 276, 21745-21753 (2001)) in vitro, no enzymatic activity was detected for the human counterpart (Walker, S. M. et al., Biochem. J. 360, 277-283 (2001)), leaving PTEN as the only so far known human PIP3-phosphatase. Since the latter study used recombinant protein of bacterial origin, enzymatic activity of human TPTE with eucaryotically produced protein was reassessed. The phosphatase and C2 domains of TPTE and PTEN fused to eGFP were expressed in HEK-293 cells, the proteins purified by immunoprecipitation with anti-eGFP antibody coupled protein ...

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

PUM

PropertyMeasurementUnit
temperaturesaaaaaaaaaa
pHaaaaaaaaaa
timeaaaaaaaaaa
Login to View More

Abstract

The present invention relates to methods which make possible to assess and / or prognose a cancer disease, the metastatic behaviour of a cancer disease and / or the occurrence of a relapse of cancer. In particular, the methods of the invention make possible to assess and / or prognose the occurrence of cancer metastasis, in particular distant metastasis. Preferably, the methods of the invention allow to discriminate malign from benign conditions.

Description

RELATED APPLICATIONS[0001]This application is a Continuation Application of International Application Number PCT / EP2007 / 008777, filed Oct. 9, 2007 and claiming priority benefit of European Patent Application Number 06 021 434.3, filed on Oct. 12, 2006, the contents of which are incorporated herein by reference in their entireties.FEDERALLY SPONSORED RESEARCH OR DEVELOPMENT[0002][Not Applicable]BACKGROUND OF THE INVENTION[0003]Despite interdisciplinary approaches and exhaustive use of classical therapeutic procedures, cancers are still among the leading causes of death.[0004]In particular, metastasis is one of the most critical factors responsible for the failure of cancer treatment. Although protein expression profiling, gene array analysis and determination of critical factors in tumor tissue have improved the prognostic classification of tumors, it is still difficult to predict the risk of metastasis analyzing the resected primary tumor. After complete tumor resection survival usu...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

Application Information

Patent Timeline
no application Login to View More
Patent Type & Authority Applications(United States)
IPC IPC(8): A61K31/7088G01N33/53C12Q1/68A61P35/00
CPCC12Q1/6886C12Q2600/118C12Q2600/154C12Q2600/158G01N33/57484A61K39/39558G01N2333/715C12N15/8218A61K47/484C12N2310/11A61K31/7088G01N33/57492A61K47/6807A61P35/00A61P35/04C07K16/28C07K16/2866C07K16/40C07K2317/76C12N15/1138C12N2310/14G01N2333/7158G01N2333/916
Inventor SAHIN, UGURTURECI, OZLEMKOSLOWSKI, MICHAEL
Owner GANYMED PHARMA AG
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Patsnap Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Patsnap Eureka Blog
Learn More
PatSnap group products

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic, Popular Technical Reports.

© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap|About US| Contact US: help@patsnap.com